Nuveen California Municipal Value Fund
Change company Symbol lookup
Select an option...
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc
GAB-H Gabelli Equity Trust Inc
GAB-G Gabelli Equity Trust Inc
AAL American Airlines Group Inc
ARKF ARK Fintech Innovation ETF
PNR Pentair PLC
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
Go

Company profile

Nuveen California Municipal Value Fund, Inc. (the Fund) is a diversified, closed-end management investment company. The Fund's objective is to seeks current income exempt from both regular federal income taxes and California personal income tax. Its secondary investment objective is the enhancement of portfolio value. The Fund invests in municipal securities that are exempt from federal and California state income taxes. The Fund invests at least 80% of its managed assets in securities rated, at the time of investment, investment grade or, if they are unrated, are judged by the manager to be of comparable quality. The Fund also invest up to 20% of its managed assets in municipal securities rated below investment quality or judged by the manager to be of comparable quality, of which up to 10% of its managed assets may be rated below B-/B3 or of comparable quality. It also invests in inverse floating rate municipal securities. Its investment adviser is Nuveen Fund Advisors, LLC.

Price
Delayed
$8.73
Day's Change
0.01 (0.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.82
Day's Low
8.68
Volume
(Heavy Day)

Today's volume of 45,129 shares is on pace to be much greater than NCA's 10-day average volume of 51,221 shares.

45,129

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NEO

11:01 am ET January 22, 2023 (Newsfile) Print

New York, New York--(Newsfile Corp. - January 22, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NeoGenomics, Inc. (NASDAQ: NEO) between February 27, 2020 and April 26, 2022, both dates inclusive (the "Class Period"), of the important February 6, 2023 lead plaintiff deadline.

SO WHAT: If you purchased NeoGenomics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the NeoGenomics class action, go to https://rosenlegal.com/submit-form/?case_id=4888 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) it was not a "one-stop-shop" for cancer testing because it did not offer the most technologically advanced NGS tests, which led to a significant decrease in revenue as current and prospective customers went elsewhere for their testing needs; (2) costs were not fixed because NeoGenomics needed to hire additional employees to process more complex customized testing demanded by customers utilizing the Company's outdated portfolio of tests, leading to operational challenges, decrease lab efficiency, and increased testing turnaround times; and as a result (3) NeoGenomics violated federal healthcare laws and regulations related to fraud, waste, and abuse. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the NeoGenomics class action, go to https://rosenlegal.com/submit-form/?case_id=4888 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152044

comtex tracking

COMTEX_423102823/2523/2023-01-22T11:01:02

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.